Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amgen (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 133,536,896
  • Shares Outstanding, K 729,670
  • Annual Sales, $ 22,991 M
  • Annual Income, $ 7,722 M
  • 36-Month Beta 1.36
  • Price/Sales 5.80
  • Price/Cash Flow 12.48
  • Price/Book 4.20

Price Performance

See More
Period Period Low Period High Performance
1-Month
181.20 +0.39%
on 10/16/17
190.00 -4.26%
on 10/05/17
-5.57 (-2.97%)
since 09/15/17
3-Month
166.52 +9.24%
on 08/18/17
191.10 -4.81%
on 09/14/17
+4.77 (+2.69%)
since 07/14/17
52-Week
133.64 +36.11%
on 11/04/16
191.10 -4.81%
on 09/14/17
+20.00 (+12.35%)
since 10/14/16

Most Recent Stories

More News
Amgen And Boston Children's Hospital Enter A Collaboration To Find New Genes And Drug Targets For Severe Pain Syndromes

Amgen (NASDAQ:AMGN) and Boston Children's Hospital today announced that they have entered into a neuroscience research collaboration aimed at identifying novel pain targets based on human genetic analyses....

AMGN : 181.90 (-0.61%)
Pharma Industry Outlook - October 2017

Pharma Industry Outlook - October 2017

TEVA : 14.71 (-1.80%)
GILD : 79.95 (-1.50%)
AMGN : 181.90 (-0.61%)
PFE : 35.98 (-0.99%)
Amgen Foundation Awards Khan Academy $3 Million To Support Development Of Free Comprehensive Biology Lessons

The Amgen Foundation today announced a three-year, $3 million grant to Khan Academy to develop comprehensive new biology lessons. The Amgen Foundation is the exclusive sponsor of Khan Academy's biology...

AMGN : 181.90 (-0.61%)
Mylan Gets Complete Response Letter For Biosimilar Neulasta

Mylan (MYL) suffered a setback following the FDA's CRL for the company's BLA for MYL-1401H, a proposed biosimilar of Neulasta.

MYL : 38.18 (+0.61%)
TEVA : 14.71 (-1.80%)
RHHBY : 31.1800 (-0.73%)
AMGN : 181.90 (-0.61%)
Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit

With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.

CELG : 136.71 (+0.18%)
VRTX : 154.70 (+1.17%)
CLVS : 84.58 (+0.37%)
ABBV : 91.04 (+0.41%)
REGN : 445.68 (+0.61%)
AMGN : 181.90 (-0.61%)
BIIB : 335.68 (-0.58%)
Amgen Label Expansion Application for Prolia Accepted by FDA

Amgen (AMGN) announced that the FDA has accepted its regulatory application in the U.S. seeking label expansion for Prolia for treating patients with glucocorticoid-induced osteoporosis (GIOP).

CELG : 136.71 (+0.18%)
PDLI : 3.51 (+1.15%)
VRTX : 154.70 (+1.17%)
AMGN : 181.90 (-0.61%)
Stonegate Capital Partners Updates Coverage on Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI)

DALLAS, TX / ACCESSWIRE / October 10, 2017 / Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI):

SPPI : 13.94 (+4.34%)
AMGN : 181.90 (-0.61%)
FDA Accepts Supplemental Biologics License Application For Prolia® (Denosumab) In Glucocorticoid-Induced Osteoporosis

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Prolia® (denosumab) for the treatment...

AMGN : 181.90 (-0.61%)
Forget Teva (TEVA), Buy These 5 Drug Stocks Instead

With another challenge cropping up for Teva (TEVA) in the form of earlier-than-expected generic competition for the 40 mg dose of Copaxone, here is a look at 5 drug stocks that look better-positioned.

MYL : 38.18 (+0.61%)
CELG : 136.71 (+0.18%)
LGND : 141.74 (-0.91%)
VRTX : 154.70 (+1.17%)
TEVA : 14.71 (-1.80%)
AMGN : 181.90 (-0.61%)
PFE : 35.98 (-0.99%)
Cancer Space Last Week Update: Pipeline Expansion in Focus

Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.

CTMX : 20.50 (-3.57%)
LLY : 85.95 (-0.69%)
ECYT : 4.30 (-0.81%)
SGEN : 62.89 (-0.17%)
CLSN : 4.08 (-1.69%)
AMGN : 181.90 (-0.61%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Support & Resistance

2nd Resistance Point 185.43
1st Resistance Point 183.67
Last Price 181.90
1st Support Level 180.67
2nd Support Level 179.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart